Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
Conditions: Gastric Adenocarcinoma; Pancreatic Cancer; Gastroesophageal Junction Adenocarcinoma Intervention: Drug: CT041 autologous CAR T-cell injection Sponsors: Carsgen Therapeutics, Ltd.; Beijing Cancer Hospital; Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastroenterology | Hospitals | Research | Study